Skip to Main Content

A spat has erupted in Canada over the amount of money that drug makers spend each year on R&D in the country and it comes as the government takes a closer look at coping with high prices.

Earlier this week, a government agency called the Patented Medicine Prices Review Board released a report showing that industry R&D investment was 4.4 percent of Canadian sales in 2016. This is a problem for the pharmaceutical industry, which committed 30 years ago to maintain annual R&D spending in Canada at 10 percent or more each year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.